NURS 8100 Week 4 Policy Analysis Example

Closing the Perinatal Depression Treatment Gap in Medicaid: A State Plan Amendment, Its Financing, and the Caseload Arithmetic That Decides Whether It Works

Student Name

Doctor of Nursing Practice Program, Walden University

NURS 8100: Healthcare Policy and Analysis

Instructor Name

Month Day, Year

Problem Definition: Perinatal Depression in a Medicaid Birth Population

The state Medicaid agency in this analysis is a composite, and every state-level figure below is an illustrative assumption carried through the arithmetic rather than a real program's data. That program finances 52,000 births a year. At a perinatal depression prevalence of 13.0 percent, about 6,760 people in each annual birth cohort meet criteria in the year around delivery. Maternal mortality review committees across 36 states found mental health conditions, including suicide and overdose, to be the leading underlying cause of pregnancy-related death (Centers for Disease Control and Prevention, 2022). The denominator matters more than the percentage, because 6,760 is the number every option in this analysis has to reach, and none of them reaches all of it.

Current policy has already solved the easy part. Screening is covered, the U.S. Preventive Services Task Force recommends counseling interventions for people at increased risk, and both prenatal and postpartum visits carry a screening expectation (U.S. Preventive Services Task Force, 2019). Screening is not the constraint. In this composite program 61.0 percent of the cohort is screened at least once, 38.0 percent of those screening positive have any documented follow-up contact within 30 days, and about 20.0 percent of the 6,760, or 1,352 people, begin and complete a course of evidence-based treatment. That leaves 5,408 people a year who are identified or readily identifiable and then not treated.

The failure is structural rather than clinical. A practice can screen inside a visit it is already paid for, but the treatment it then tries to arrange sits in a specialty behavioral health system with waits measured in months. What the evidence supports is not referral. It is collaborative care: a care manager holding a panel inside the practice, a registry, treatment adjusted to a repeated symptom score, and a psychiatric consultant who reviews cases without seeing most of them. A Cochrane review of 79 trials found collaborative care improved depression and anxiety outcomes over usual care (Archer et al., 2012). The model is proven. Until a payer creates a billable unit for it, no practice can staff it.

Criteria for Comparison and the Four Instruments Considered

Options are compared here against five criteria, stated before the options so the comparison is not built backward from a preferred answer. Reach is the share of the 6,760 an instrument can touch, including the population served by federally qualified health centers and rural health clinics. Durability is whether the authority expires. Financing leverage is how much federal money each state dollar draws. Administrative burden is the agency work and the time to first payment. Equity is whether the instrument reaches rural and safety net practices rather than only large integrated systems. Cost per additional person treated is reported alongside these rather than as a sixth criterion.

A grant program to selected clinics is the fastest instrument and the weakest. It scores well on time to effect and poorly on everything else: reach stops at the awardees, the authority expires with the appropriation, and general fund grant dollars draw no federal match. A managed care contract requirement is the second option and is more attractive than it turns out to be. The agency can require plans to cover integrated behavioral health, but plans buy what the delivery system can bill, and payment for the model has to be actuarially sound using utilization data that does not yet exist. The requirement also leaves the fee-for-service population, small here but disproportionately rural, untouched.

A Section 1115 demonstration is the third option and the one most likely to be proposed in a meeting. It is the wrong tool here. A demonstration must be budget neutral to the federal government, it is time limited, and it carries renewal risk that no practice will hire a care manager against. The fourth option is a state plan amendment adding the psychiatric collaborative care codes to the fee schedule, with the parallel code that lets federally qualified health centers and rural health clinics bill the model outside their per-visit prospective rate (Centers for Medicare & Medicaid Services, 2024). A state plan amendment is an entitlement change: permanent until amended, statewide, and matched.

Financing the Recommendation: The Match, the Episode, and the State Share

Medicaid is financed jointly, and the federal share is set by a statutory formula tied to state per capita income (KFF, 2024). This composite state has a federal medical assistance percentage of 62.0 percent, so the general fund pays 38 cents of every service dollar and each state dollar draws $1.63 of federal money. That ratio is the whole financial argument for putting the model in the state plan instead of a grant. Priced at 100 percent of the Medicare rate, the collaborative care codes pay an average of $135.00 for each month a patient is engaged and treated, so a six-month episode is worth about $810.00 in total computable expenditure.

The recommendation targets treatment for 45.0 percent of the cohort by year three, or 3,042 people, which is 1,690 more than the 1,352 treated now. At $810.00 an episode those 1,690 episodes cost $1,368,900 in total computable expenditure, of which the state share at 38.0 percent is $520,182 and the federal share is $848,718. A second line finances what no fee schedule pays for: a statewide psychiatric consultation service and a shared registry, budgeted at $1,300,000 and claimed as an administrative expenditure at the 50 percent administrative match, so the state share is $650,000. Total state general fund exposure at full uptake is $1,170,182 against $2,668,900 of all-funds spending, or $692 for each additional person treated.

This analysis does not claim the program pays for itself, and a policy memo that does should be read with suspicion. Offset evidence for collaborative care is strongest over multi-year horizons and in populations carrying more comorbidity than a birth cohort, and a budget office will discount a saving it cannot see inside the biennium. The defensible claim is narrower and stronger: $692 of state money buys one more completed course of measurement-based treatment, and the legislature can decide whether that price is worth paying. The claim also survives the budget neutrality test a demonstration would face, since a state plan amendment carries no such test (Medicaid and CHIP Payment and Access Commission, 2024).

Implementation Feasibility, Evaluation, and the Failure Modes to Watch

Feasibility turns on one calculation the policy conversation usually skips. A behavioral health care manager costs about $105,800 a year loaded, and at $135.00 per engaged month a practice has to bill 784 months a year to cover that position. That is a panel of 66 patients held every month, not 66 patients seen at some point in the year. The panel this model is designed around is 60 to 80, so the rate works at the top of that range and only if the psychiatric consultant's time is paid from somewhere else, which is what the state consultation line is for. Statewide, 1,690 episodes are 10,140 billable months, or about 13 full-time care managers, phased over three years.

The administrative path is ordinary and slow. A state plan amendment can take effect on the first day of the quarter in which it is submitted, but the federal review clock resets when the agency is asked for additional information, so an amendment filed in the first quarter should be planned for payment in the third. Managed care contract amendments run on their own annual cycle, and the actuary setting year one rates has no utilization history for a service that does not exist yet, which argues for a risk corridor in the first rating period. Provider readiness is the slower constraint: a registry, a workflow, and a hired care manager take a practice about two quarters.

Evaluation belongs inside the amendment rather than after it. Three measures carry the weight. The share of the birth cohort with a documented screen and a documented follow-up within 30 days, which the federal core measure sets already define. The engaged months billed per care manager full-time equivalent, which predicts whether practices stay in. And the share of treated patients whose symptom score falls by half within 16 weeks, the only one of the three that reports whether treatment happened rather than whether billing happened. Two failure modes deserve watching from the first quarter. A code with a rate too low to staff produces adoption on paper and no panels. A registry requirement with no funded implementation support produces the same result more slowly.

References

Archer, J., Bower, P., Gilbody, S., Lovell, K., Richards, D., Gask, L., Dickens, C., & Coventry, P. (2012). Collaborative care for depression and anxiety problems. Cochrane Database of Systematic Reviews, 10, CD006525. https://doi.org/10.1002/14651858.CD006525.pub2

Centers for Disease Control and Prevention. (2022). Pregnancy-related deaths: Data from Maternal Mortality Review Committees in 36 US states, 2017-2019. U.S. Department of Health and Human Services. https://www.cdc.gov/maternal-mortality/

Centers for Medicare & Medicaid Services. (2024). Behavioral health integration services [MLN booklet]. U.S. Department of Health and Human Services. https://www.cms.gov/

KFF. (2024). Medicaid financing: The basics. KFF. https://www.kff.org/medicaid/

Medicaid and CHIP Payment and Access Commission. (2024). Report to Congress on Medicaid and CHIP. Medicaid and CHIP Payment and Access Commission. https://www.macpac.gov/

U.S. Preventive Services Task Force. (2019). Interventions to prevent perinatal depression: US Preventive Services Task Force recommendation statement. JAMA, 321(6), 580-587. https://doi.org/10.1001/jama.2019.0007